Login Register Cart 0
Generic placeholder image

Current Drug Delivery

Editor-in-Chief

ISSN (Print): 1567-2018
ISSN (Online): 1875-5704

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Nanotechnology-based Medicinal Products and Patents: A Promising Way to Treat Psoriasis

Author(s): Faraat Ali*, Kumari Neha, Kamna Sharma, Shaik Khasimbi and Garima Chauhan

Volume 19, Issue 5, 2022

Published on: 25 March, 2022

Page: [587 - 599] Pages: 13

DOI: 10.2174/1567201819666220126163943

Price: $65

Abstract

Psoriasis is an autoimmune skin disorder that is characterised by chronic inflammation and erythematous scaly patches. It has a significant impact on the patient's quality of life and can cause psychological stress. There are several aspects that cause psoriasis, for instance, environmental issues, immune disorders, bacterial infections, and genetic issues. Plentiful therapeutic means or treatments are accessible, but not any of them can completely and effectively cure psoriasis without hindering patient compliance. Hence, it becomes challenging to discover a new drug moiety or any drug delivery method to cure psoriasis. Conventional treatment of psoriasis involves anti-inflammatory agents, immune suppressants, phototherapy, and biological treatment, which were given in different forms such as topical, oral, or systemic formulations, but these all were unsuccessful to accomplish complete reduction of psoriasis as well as causing adverse side effects. In terms of dose frequency, doses, efficacy, and side effects, nanotechnology-based new formulations are the most promising prospects for addressing the challenges and limits associated with present psoriasis formulations. Hence, our major goal of this review is to present various advanced nanotechnological approaches for the effective topical treatment of psoriasis. In short, nano-formulations continue to be formed as very promising modalities in the treatment of psoriasis as they suggest improved penetration, targeted delivery, increased safety, and efficacy.

Keywords: Psoriasis, nanotechnology, nanocarrier, delivery system, phototherapy, anti-inflammatory.

« Previous Next »
Graphical Abstract

[1]
Bowcock, A.M.; Barker, J.N. Genetics of psoriasis: The potential impact on new therapies. J. Am. Acad. Dermatol., 2003, 49(2)(Suppl.), S51-S56.
[http://dx.doi.org/10.1016/S0190-9622(03)01135-6] [PMID: 12894126]
[2]
Ashwin, B.K.; Rohini, R.P.; Shantanu, B.K.; Shashikant, N.D.; Payal, M.M. Psoriasis: A comprehensive review. Int. J. of Pharm. & Life Sci., 2011, 2(6), 857-877.
[3]
Lever, F.; Walter, S.G. Histopathology of the skin Boston; Massachusetts, 1981, pp. 156-164.
[4]
Moschella, L. Samuel; Pillsbury, M Donald; Hurley, J Harry, Jr. Dermatology; Saunders Company: Philadelphia, London, Toronto, 1986, p. 204.
[5]
Liu, Y.; Krueger, J.G.; Bowcock, A.M. Psoriasis: Genetic associations and immune system changes. Genes Immun., 2007, 8(1), 1-12.
[http://dx.doi.org/10.1038/sj.gene.6364351] [PMID: 17093502]
[6]
Nickoloff, B.J.; Qin, J.Z.; Nestle, F.O. Immunopathogenesis of psoriasis. Clin. Rev. Allergy Immunol., 2007, 33(1-2), 45-56.
[http://dx.doi.org/10.1007/s12016-007-0039-2] [PMID: 18094946]
[7]
Uva, L.; Miguel, D.; Pinheiro, C.; Antunes, J.; Cruz, D.; Ferreira, J.; Filipe, P. Mechanisms of action of topical corticosteroids in psoriasis. Int. J. Endocrinol., 2012, 2012, 561018.
[http://dx.doi.org/10.1155/2012/561018] [PMID: 23213332]
[8]
The latest in psoriasis treatment. 2017. (Available from: https://www.webmd.com/skin-problems-and-treatments/psoriasis/research).
[9]
Schön, M.P.; Boehncke, W.H. Psoriasis. N. Engl. J. Med., 2005, 352(18), 1899-1912.
[http://dx.doi.org/10.1056/NEJMra041320] [PMID: 15872205]
[10]
Henseler, T.; Christophers, E. Psoriasis of early and late onset: Characterization of two types of psoriasis vulgaris. J. Am. Acad. Dermatol., 1985, 13(3), 450-456.
[http://dx.doi.org/10.1016/S0190-9622(85)70188-0] [PMID: 4056119]
[11]
Capon, F.; Munro, M.; Barker, J.; Trembath, R. Searching for the major histocompatibility complex psoriasis susceptibility gene. J. Invest. Dermatol., 2002, 118(5), 745-751.
[http://dx.doi.org/10.1046/j.1523-1747.2002.01749.x] [PMID: 11982750]
[12]
Chandra, A.; Ray, A.; Senapati, S.; Chatterjee, R. Genetic and epigenetic basis of psoriasis pathogenesis. Mol. Immunol., 2015, 64(2), 313-323.
[http://dx.doi.org/10.1016/j.molimm.2014.12.014] [PMID: 25594889]
[13]
Rahman, P.; Elder, J.T. Genetic epidemiology of psoriasis and psoriatic arthritis. Ann. Rheum. Dis., 2005, 64(Suppl. 2), ii37-ii39.
[http://dx.doi.org/10.1136/ard.2004.030775] [PMID: 15708933]
[14]
Gupta, R.; Debbaneh, M.G.; Liao, W. Genetic epidemiology of psoriasis. Curr. Dermatol. Rep., 2014, 3(1), 61-78.
[http://dx.doi.org/10.1007/s13671-013-0066-6] [PMID: 25580373]
[15]
Capon, F. The genetic basis of psoriasis. Int. J. Mol. Sci., 2017, 18(12), 2526.
[http://dx.doi.org/10.3390/ijms18122526] [PMID: 29186830]
[16]
Gudjonsson, J.E.; Johnston, A. Current understanding of the genetic basis of psoriasis. Expert Rev. Clin. Immunol., 2009, 5(4), 433-443.
[http://dx.doi.org/10.1586/eci.09.13] [PMID: 20477039]
[17]
Nickoloff, B.J. The immunologic and genetic basis of psoriasis. Arch. Dermatol., 1999, 135(9), 1104-1110.
[http://dx.doi.org/10.1001/archderm.135.9.1104] [PMID: 10490116]
[18]
Pradhan, M.; Alexander, A.; Singh, M.R.; Singh, D.; Saraf, S.; Saraf, S. Ajazuddin, Understanding the prospective of nano-formulations towards the treatment of psoriasis. Biomed. Pharmacother., 2018, 107, 447-463.
[http://dx.doi.org/10.1016/j.biopha.2018.07.156] [PMID: 30103117]
[19]
Pradhan, M.; Singh, D.; Singh, M.R. Novel colloidal carriers for psoriasis: current issues, mechanistic insight and novel delivery approaches. J. Control. Release, 2013, 170(3), 380-395.
[http://dx.doi.org/10.1016/j.jconrel.2013.05.020] [PMID: 23770117]
[20]
Menter, Alan Guidelines of care for the management of psoriasis and psoriatic arthritics. J. Am. Acad. Dermatol., 2009, 60, 643-659.
[http://dx.doi.org/10.1016/j.jaad.2008.12.032] [PMID: 19217694]
[21]
Wozel, G. Psoriasis treatment in difficult locations: Scalp, nails, and intertriginous areas. Clin. Dermatol., 2008, 26(5), 448-459.
[http://dx.doi.org/10.1016/j.clindermatol.2007.10.026] [PMID: 18755363]
[22]
Witman, P.M. Topical therapies for localized psoriasis. Mayo Clin. Proc., 2001, 76(9), 943-949.
[http://dx.doi.org/10.1016/S0025-6196(11)62116-2] [PMID: 11560307]
[23]
Lebwohl, M. The role of salicylic acid in the treatment of psoriasis. Int. J. Dermatol., 1999, 38(1), 16-24.
[http://dx.doi.org/10.1046/j.1365-4362.1999.00500.x] [PMID: 10065604]
[24]
Vinay, K. Cotran S Ramzi, Robbins L Stanley Basic pathology, 6th ed; Harcourt India Private Ltd., 2001, p. 701.
[25]
Mohan Harsh Text -Book Pathology The skin, 4th edition; 763.
[26]
Petit, R.G.; Cano, A.; Ortiz, A.; Espina, M.; Prat, J.; Muñoz, M.; Severino, P.; Souto, E.B.; García, M.L.; Pujol, M.; Sánchez-López, E. Psoriasis: From pathogenesis to pharmacological and nano-technological-based therapeutics. Int. J. Mol. Sci., 2021, 22(9), 4983.
[http://dx.doi.org/10.3390/ijms22094983] [PMID: 34067151]
[27]
Das, Patrick Rajeev Jain kumar, Arun; Ramesh, V. Current concept in the pathogenesis of psoriasis. Indian J. Dermatol., 2009, 54(1), 7-12.
[http://dx.doi.org/10.4103/0019-5154.48977] [PMID: 20049260]
[28]
Tzu, Julia; Adam, J.; Mamelak, Daniel N. Current advancements in the treatment of psoriasis: Immunobiologic agents. Clin. Appl. Immunol., 2006, 54, 99-130.
[http://dx.doi.org/10.1016/j.cair.2006.06.003]
[29]
Application to dermatology of International Classification of Disease (ICD-10)- ICD sorted by code: L40.000-L41.000, The International League of Dermatological Societies.
[30]
Yosipovitch, G.; Tang, M.B.Y. Practical management of psoriasis in elderly. Drugs Aging, 2002, 19(11), 847-867.
[http://dx.doi.org/10.2165/00002512-200219110-00003] [PMID: 12428994]
[31]
Monteiro-Riviere, N.A. Structure and function of skin. Toxicology of the Skin; Informa Healthcare: New York, 2010.
[32]
Huang, T.H.; Lin, C.F.; Alalaiwe, A.; Yang, S.C.; Fang, J.Y. Apoptotic or antiproliferative activity of natural products against keratinocytes for the treatment of psoriasis. Int. J. Mol. Sci., 2019, 20(10), 2558.
[http://dx.doi.org/10.3390/ijms20102558] [PMID: 31137673]
[33]
Deng, S.; May, B.H.; Zhang, A.L.; Lu, C.; Xue, C.C. Topical herbal medicine combined with pharmacotherapy for psoriasis: A systematic review and meta-analysis. Arch. Dermatol. Res., 2013, 305(3), 179-189.
[http://dx.doi.org/10.1007/s00403-013-1316-y] [PMID: 23354931]
[34]
Rout, S.K.; Tripathy, B.C.; Kar, B.R. Natural green alternatives to psoriasis treatment-A review. Global J. Pharm. Pharm. Sci., 2017, 4(1), 001-007.
[35]
Singh, K.K.; Tripathy, S. Natural treatment alternative for psoriasis: A review on herbal resources. J. Appl. Pharm. Sci., 2014, 4(11), 114-121.
[36]
Bonesi, M.; Loizzo, M.R.; Provenzano, E.; Menichini, F.; Tundis, R. Anti-psoriasis agents from natural plant sources. Curr. Med. Chem., 2016, 23(12), 1250-1267.
[http://dx.doi.org/10.2174/0929867323666160321121819] [PMID: 26997153]
[37]
Nguyen, U.T.; Nguyen, L.T.H.; Kim, B.A.; Choi, M.J.; Yang, I.J.; Shin, H.M. Natural compound mixture, containing emodin, genipin, chlorogenic acid, cimigenoside, and ginsenoside Rb1, ameliorates psoriasis-like skin lesions by suppressing inflammation and proliferation in keratinocytes. Evid. Based Complement. Alternat. Med., 2020, 2020, 9416962.
[http://dx.doi.org/10.1155/2020/9416962] [PMID: 33149756]
[38]
de Las Heras Alarcon, C.; Pennadam, S.; Alexander, C. Stimuli responsive polymers for biomedical applications. Chem. Soc. Rev., 2005, 34(3), 276-285.
[http://dx.doi.org/10.1039/B406727D] [PMID: 15726163]
[39]
Wagner, V.; Dullaart, A.; Bock, A.K.; Zweck, A. The emerging nanomedicine landscape. Nat. Biotechnol., 2006, 24(10), 1211-1217.
[http://dx.doi.org/10.1038/nbt1006-1211] [PMID: 17033654]
[40]
Bawa, P.; Pillay, V.; Choonara, Y.E.; du Toit, L.C. Stimuli-responsive polymers and their applications in drug delivery. Biomed. Mater., 2009, 4(2), 022001.
[http://dx.doi.org/10.1088/1748-6041/4/2/022001] [PMID: 19261988]
[41]
Kaur, R.; Garg, T. DAS, Gupta U.; Gupta, p.; Rath, G.; Goyal, A.K. Preparation and characterization of spray-dried inhalable powders containing nanoaggregates for pulmonary delivery of anti-tubercular drugs. Artif. Cells Nanomed. Biotechnol., 2014, 44(1), 182-187.
[http://dx.doi.org/10.3109/21691401.2014.930747] [PMID: 24992699]
[42]
Ali, M.F.; Salah, M.; Rafea, M.; Saleh, N. Liposomal methotrexate hydrogel for treatment of localized psoriasis: Preparation, characterization and laser targeting. Med. Sci. Monit., 2008, 14(12), PI66-PI74.
[PMID: 19043379]
[43]
Goyal, G.; Garg, T.; Malik, B.; Chauhan, G.; Rath, G.; Goyal, A.K. Development and characterization of niosomal gel for topical delivery of benzoyl peroxide. Drug Deliv., 2015, 22(8), 1027-1042.
[http://dx.doi.org/10.3109/10717544.2013.855277] [PMID: 24251352]
[44]
Kataria, K.; Sharma, A.; Garg, T.; Goyal, A.K.; Rath, G. Novel technology to improve drug loading in polymeric nanofibers. Drug Deliv. Lett., 2014, 4(1), 79-86.
[http://dx.doi.org/10.2174/22103031113036660018]
[45]
Kaur, G.; Garg, T.; Rath, G.; Goyal, A.K. Archaeosomes: An excellent carrier for drug and cell delivery. Drug Deliv., 2016, 23(7), 2497-2512.
[http://dx.doi.org/10.3109/10717544.2015.1019653] [PMID: 25777339]
[46]
Wilczewska, A.Z.; Niemirowicz, K.; Markiewicz, K.H.; Car, H. Nanoparticles as drug delivery systems. Pharmacol. Rep., 2012, 64(5), 1020-1037.
[http://dx.doi.org/10.1016/S1734-1140(12)70901-5] [PMID: 23238461]
[47]
Knudsen, N.O.; Rønholt, S.; Salte, R.D.; Jorgensen, L.; Thormann, T.; Basse, L.H.; Hansen, J.; Frokjaer, S.; Foged, C. Calcipotriol delivery into the skin with PEGylated liposomes. Eur. J. Pharm. Biopharm., 2012, 81(3), 532-539.
[http://dx.doi.org/10.1016/j.ejpb.2012.04.005] [PMID: 22538098]
[48]
Maherani, B.; Arab-Tehrany, E.; Mozafari, R. M.; Gaiani, C.; Linder, M. Liposomes: a review of manufacturing techniques and targeting strategies. Curr. Nanosci., 2011, 7(3), 436-452.
[http://dx.doi.org/10.2174/157341311795542453]
[49]
Singh, H.; Sharma, R.; Joshi, M.; Garg, T.; Goyal, A.K.; Rath, G. Transmucosal delivery of docetaxel by mucoadhesive polymeric nanofibers. Artif. Cells Nanomed. Biotechnol., 2015, 43(4), 263-269.
[http://dx.doi.org/10.3109/21691401.2014.885442http://dx.doi.org/24621011]
[50]
Singh, K.; Arora, N.; Garg, T. RFID: A trustable security tool in pharmaceutical industry. Am. J. Pharm. Tech., 2012, 2, 113-127.
[51]
Bikkad, M.L.; Nathani, A.H.; Mandlik, S.K.; Shrotriya, S.N.; Ranpise, N.S. Halobetasol pr6opionate-loaded solid lipid nanoparticles (SLN) for skin targeting by topical delivery. J. Liposome Res., 2013, 113-123.
[http://dx.doi.org/10.3109/08982104.2013.843192]
[52]
Singh, K.; Arora, N.; Garg, T. Superbug: Antimicrobial resistance due to NDM-1. Inst. Pharm. Life Sci., 2012, 2, 58-66.
[http://dx.doi.org/10.3109/08982104.2013.843192]
[53]
Mandawgade, S.D.; Patravale, V.B. Development of SLNs from natural lipids: Application to topical delivery of tretinoin. Int. J. Pharm., 2008, 363(1-2), 132-138.
[http://dx.doi.org/10.1016/j.ijpharm.2008.06.028] [PMID: 18657601]
[54]
Rabinow, B.E. Nanosuspensions in drug delivery. Nat. Rev. Drug Discov., 2004, 3(9), 785-796.
[http://dx.doi.org/10.1038/nrd1494] [PMID: 15340388]
[55]
Müller, R.H.; Radtke, M.; Wissing, S.A. Nanostructured lipid matrices for improved microencapsulation of drugs. Int. J. Pharm., 2002, 242(1-2), 121-128.
[http://dx.doi.org/10.1016/S0378-5173(02)00180-1] [PMID: 12176234]
[56]
Shangguan, M.; Lu, Y.; Qi, J.; Han, J.; Tian, Z.; Xie, Y.; Hu, F.; Yuan, H.; Wu, W. Binary lipids-based nanostructured lipid carriers for improved oral bioavailability of silymarin. J. Biomater. Appl., 2014, 28(6), 887-896.
[http://dx.doi.org/10.1177/0885328213485141] [PMID: 24008629]
[57]
Ungaro, F.; Vanbever, R. Improving the efficacy of inhaled drugs for severe lung diseases: Emerging pulmonary delivery strategies. Adv. Drug Deliv. Rev., 2014, 75, 1-2.
[http://dx.doi.org/10.1016/j.addr.2014.08.001] [PMID: 25109852]
[58]
Weber, S.; Zimmer, A.; Pardeike, J. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) for pulmonary application: A review of the state of the art. Eur. J. Pharm. Biopharm., 2014, 86(1), 7-22.
[http://dx.doi.org/10.1016/j.ejpb.2013.08.013] [PMID: 24007657]
[59]
Beloqui, A.; Coco, R.; Memvanga, P.B.; Ucakar, B.; des Rieux, A.; Préat, V. pH-sensitive nanoparticles for colonic delivery of curcumin in inflammatory bowel disease. Int. J. Pharm., 2014, 473(1-2), 203-212.
[http://dx.doi.org/10.1016/j.ijpharm.2014.07.009] [PMID: 25014369]
[60]
Gartziandia, O.; Herran, E.; Pedraz, J.L.; Carro, E.; Igartua, M.; Hernandez, R.M. Chitosan coated nanostructured lipid carriers for brain delivery of proteins by intranasal administration. Colloids Surf. B Biointerfaces, 2015, 134, 304-313.
[http://dx.doi.org/10.1016/j.colsurfb.2015.06.054] [PMID: 26209963]
[61]
Khurana, S.; Jain, N.K.; Bedi, P.M. Development and characterization of a novel controlled release drug delivery system based on nanostructured lipid carriers gel for meloxicam. Life Sci., 2013, 93(21), 763-772.
[http://dx.doi.org/10.1016/j.lfs.2013.09.027] [PMID: 24113071]
[62]
Schwarz, J.C.; Baisaeng, N.; Hoppel, M.; Löw, M.; Keck, C.M.; Valenta, C. Ultra-small NLC for improved dermal delivery of coenyzme Q10. Int. J. Pharm., 2013, 447(1-2), 213-217.
[http://dx.doi.org/10.1016/j.ijpharm.2013.02.037] [PMID: 23438979]
[63]
Beloqui, A.; Solinís, M.A.; Rodríguez-Gascón, A.; Almeida, A.J.; Préat, V. Nanostructured lipid carriers: Promising drug delivery systems for future clinics. Nanomedicine, 2016, 12(1), 143-161.
[http://dx.doi.org/10.1016/j.nano.2015.09.004] [PMID: 26410277]
[64]
Kaur, M.; Garg, T.; Rath, G.; Goyal, A.K. Current nanotechnological strategies for effective delivery of bioactive drug molecules in the treatment of tuberculosis. Crit. Rev. Ther. Drug Carrier Syst., 2014, 31(1), 49-88.
[http://dx.doi.org/10.1615/CritRevTherDrugCarrierSyst.2014008285] [PMID: 24579767]
[65]
Kaur, M.; Malik, B.; Garg, T.; Rath, G.; Goyal, A.K. Development and characterization of guar gum nanoparticles for oral immunization against tuberculosis. Drug Deliv., 2015, 22(3), 328-334.
[http://dx.doi.org/10.3109/10717544.2014.894594] [PMID: 24611942]
[66]
Kaur, N.; Garg, T.; Goyal, A.K.; Rath, G. Formulation, optimization and evaluation of curcumin-beta-cyclodextrin-loaded sponge for effective drug delivery in thermal burns chemotherapy. Drug Deliv., 2016, 23(7), 2245-2254.
[http://dx.doi.org/10.3109/10717544.2014.993486] [PMID: 25268151]
[67]
Azeem, A.; Anwer, M.K.; Talegaonkar, S. Niosomes in sustained and targeted drug delivery: Some recent advances. J. Drug Target., 2009, 17(9), 671-689.
[http://dx.doi.org/10.3109/10611860903079454] [PMID: 19845484]
[68]
Schreier, H.; Bouwstra, J. Liposomes and niosomes as topical drug carriers: Dermal and transdermal drug delivery. J. Control. Release, 1994, 30(1), 1-15.
[http://dx.doi.org/10.1016/0168-3659(94)90039-6]
[69]
Morie, A.; Garg, T.; Goyal, A.K.; Rath, G. Nanofibers as novel drug carrier - An overview. Artif. Cells Nanomed. Biotechnol., 2016, 44(1), 135-143.
[http://dx.doi.org/10.3109/21691401.2014.927879] [PMID: 25016918]
[70]
Rohilla, R.; Garg, T.; Goyal, A.K.; Rath, G. Herbal and polymeric approaches for liver-targeting drug delivery: Novel strategies and their significance. Drug Deliv., 2016, 23(5), 1645-1661.
[http://dx.doi.org/10.3109/10717544.2014.945018] [PMID: 25101832]
[71]
Bhalaria, M.K.; Naik, S.; Misra, A.N. Ethosomes: A novel delivery system for antifungal drugs in the treatment of topical fungal diseases. Indian J. Exp. Biol., 2009, 47(5), 368-375.
[PMID: 19579803]
[72]
Sharma, R.; Singh, H.; Joshi, M.; Sharma, A.; Garg, T.; Goyal, A.K.; Rath, G. Recent advances in polymeric electrospun nanofibers for drug delivery. Crit. Rev. Ther. Drug Carrier Syst., 2014, 31(3), 187-217.
[http://dx.doi.org/10.1615/CritRevTherDrugCarrierSyst.2014008193] [PMID: 24940748]
[73]
Singh, B.; Garg, T.; Goyal, A.K.; Rath, G. Recent advancements in the cardiovascular drug carriers. Artif. Cells Nanomed. Biotechnol., 2016, 44(1), 216-225.
[http://dx.doi.org/10.3109/21691401.2014.937868] [PMID: 25046615]
[74]
Wang, Z.; Itoh, Y.; Hosaka, Y.; Kobayashi, I.; Nakano, Y.; Maeda, I.; Umeda, F.; Yamakawa, J.; Kawase, M.; Yag, K. Novel transdermal drug delivery system with polyhydroxyalkanoate and starburst polyamidoamine dendrimer. J. Biosci. Bioeng., 2003, 95(5), 541-543.
[http://dx.doi.org/10.1016/S1389-1723(03)80059-2] [PMID: 16233454]
[75]
Mozafari, M.R.; Javanmard, R.; Raji, M. Tocosome: Novel drug delivery system containing phospholipids and tocopheryl phosphates. Int. J. Pharm., 2017, 528(1-2), 381-382.
[http://dx.doi.org/10.1016/j.ijpharm.2017.06.037] [PMID: 28619450]
[76]
Zarrabi, A.; Alipoor Amro Abadi, M.; Khorasani, S.; Mohammadabadi, M.R.; Jamshidi, A.; Torkaman, S.; Taghavi, E.; Mozafari, M.R.; Rasti, B. Nanoliposomes and tocosomes as multifunctional nanocarriers for the encapsulation of nutraceutical and dietary molecules. Molecules, 2020, 25(3), 638.
[http://dx.doi.org/10.3390/molecules25030638] [PMID: 32024189]
[77]
Gavrilescu, C-M.; Paraschiv, C.; Horjinec, P.; Sotropa, D-M.; Barbu, R-M. The advantages and disadvantages of nanotechnology. Romanian J. Oral Rehabil., 2018, 10(2), 153-159.
[78]
Sultana, F.; Manirujjaman, M.; Imran-Ul-Haque, M.A.; Sharmin, S. An overview of nanogel drug delivery system. J. Appl. Pharm. Sci., 2013, 3(8)(Suppl. 1), S95-S105.
[http://dx.doi.org/10.7324/JAPS.2013.38.S15]
[79]
Bonifácio, B.V.; Silva, P.B.; Ramos, M.A.; Negri, K.M.; Bauab, T.M.; Chorilli, M. Nanotechnology-based drug delivery systems and herbal medicines: A review. Int. J. Nanomed., 2014, 9, 1-15.
[http://dx.doi.org/10.2147/IJN.S52634] [PMID: 24363556]
[80]
Raza, K.; Singh, B.; Lohan, S.; Sharma, G.; Negi, P.; Yachha, Y.; Katare, O.P. Nano-lipoidal carriers of tretinoin with enhanced percutaneous absorption, photostability, biocompatibility and anti-psoriatic activity. Int. J. Pharm., 2013, 456(1), 65-72.
[http://dx.doi.org/10.1016/j.ijpharm.2013.08.019] [PMID: 23973754]
[81]
Zhang, Y-T.; Shen, L-N.; Zhao, J-H.; Feng, N-P. Evaluation of psoralen ethosomes for topical delivery in rats by using in vivo microdialysis. Int. J. Nanomed., 2014, 9, 669-678.
[http://dx.doi.org/10.2147/IJN.S57314] [PMID: 24489470]
[82]
Kumar, R.; Dogra, S.; Amarji, B.; Singh, B.; Kumar, S. Sharma; Vinay, K.; Mahajan, R.; Katare, O.P. Efficacy of novel topical liposomal formulation of cyclosporine in mild to moderate stable plaque psoriasis: A randomized clinical trial. JAMA Dermatol., 2016, 152(7), 807-815.
[http://dx.doi.org/10.1001/jamadermatol.2016.0859] [PMID: 27096709]
[83]
Abdelgawad, R.; Nasr, M.; Moftah, N.H.; Hamza, M.Y. Phospholipid membrane tubulation using ceramide doping “Cerosomes”: Characterization and clinical application in psoriasis treatment. Eur. J. Pharm. Sci., 2017, 101, 258-268.
[http://dx.doi.org/10.1016/j.ejps.2017.02.030] [PMID: 28232140]
[84]
Bhatia, A.; Singh, B.; Wadhwa, S.; Raza, K.; Katare, O.P. Novel phospholipid-based topical formulations of tamoxifen: Evaluation for antipsoriatic activity using mouse-tail model. Pharm. Dev. Technol., 2014, 19(2), 160-163.
[http://dx.doi.org/10.3109/10837450.2013.763260] [PMID: 23369039]
[85]
Bracke, S.; Carretero, M.; Guerrero-Aspizua, S.; Desmet, E.; Illera, N.; Navarro, M.; Lambert, J.; Del Rio, M. Targeted silencing of DEFB4 in a bioengineered skin-humanized mouse model for psoriasis: Development of siRNA SECosome-based novel therapies. Exp. Dermatol., 2014, 23(3), 199-201.
[http://dx.doi.org/10.1111/exd.12321] [PMID: 24428418]
[86]
Abu Hashim, I.I.; Abo El-Magd, N.F.; El-Sheakh, A.R.; Hamed, M.F.; Abd El-Gawad, A.E.H. Pivotal role of Acitretin nanovesicular gel for effective treatment of psoriasis: Ex vivo in vivo evaluation study. Int. J. Nanomed., 2018, 13, 1059-1079.
[http://dx.doi.org/10.2147/IJN.S156412] [PMID: 29503541]
[87]
Marepally, S.; Boakye, C.H.A.; Patel, A.R.; Godugu, C.; Doddapaneni, R.; Desai, P.R.; Singh, M. Topical administration of dual siRNAs using fusogenic lipid nanoparticles for treating psoriatic-like plaques. Nanomedicine (Lond.), 2014, 9(14), 2157-2174.
[http://dx.doi.org/10.2217/nnm.13.202] [PMID: 24593003]
[88]
Alam, M.S.; Ali, M.S.; Alam, N.; Siddiqui, M.R.; Shamim, M.; Safhi, M.M. In vivo study of clobetasol propionate loaded nanoemulsion for topical application in psoriasis and atopic dermatitis. Drug Invent. Today, 2013, 5(1), 8-12.
[http://dx.doi.org/10.1016/j.dit.2013.02.001]
[89]
Kaur, A.; Katiyar, S.S.; Kushwah, V.; Jain, S. Nanoemulsion loaded gel for topical co-delivery of clobitasol propionate and calcipotriol in psoriasis. Nanomedicine, 2017, 13, 1473-1482.
[http://dx.doi.org/10.1016/j.nano.2017.02.009] [PMID: 28259803]
[90]
Raza, K.; Katare, O.P.; Setia, A.; Bhatia, A.; Singh, B. Improved therapeutic performance of dithranol against psoriasis employing systematically optimized nanoemulsomes. J. Microencapsul., 2013, 30(3), 225-236.
[http://dx.doi.org/10.3109/02652048.2012.717115] [PMID: 23088318]
[91]
Nemati, H.; Ghahramani, M-H.; Faridi-Majidi, R.; Izadi, B.; Bahrami, G.; Madani, S.H.; Tavoosidana, G. Using siRNA-based spherical nucleic acid nanoparticle conjugates for gene regulation in psoriasis. J. Control. Release, 2017, 268, 259-268.
[http://dx.doi.org/10.1016/j.jconrel.2017.10.034] [PMID: 29074408]
[92]
Chamcheu, J.C.; Siddiqui, I.A.; Adhami, V.M.; Esnault, S.; Bharali, D.J.; Babatunde, A.S.; Adame, S.; Massey, R.J.; Wood, G.S.; Longley, B.J.; Mousa, S.A.; Mukhtar, H. Chitosan-based nanoformulated (-)-epigallocatechin-3-gallate (EGCG) modulates human keratinocyte-induced responses and alleviates imiquimod-induced murine psoriasiform dermatitis. Int. J. Nanomed., 2018, 13, 4189-4206.
[http://dx.doi.org/10.2147/IJN.S165966] [PMID: 30057446]
[93]
Mao, K-L.; Fan, Z-L.; Yuan, J-D.; Chen, P.P.; Yang, J.J.; Xu, J. ZhuGe, D.L.; Jin, B.H.; Zhu, Q.Y.; Shen, B.X.; Sohawon, Y.; Zhao, Y.Z.; Xu, H.L. Skin-penetrating polymeric nanoparticles incorporated in silk fibroin hydrogel for topical delivery of curcumin to improve its therapeutic effect on psoriasis mouse model. Colloids Surf. B Biointerfaces, 2017, 160, 704-714.
[http://dx.doi.org/10.1016/j.colsurfb.2017.10.029] [PMID: 29035818]
[94]
Divya, G.; Panonnummal, R.; Gupta, S.; Jayakumar, R.; Sabitha, M. Acitretin aloe-emodin loaded chitin nanogel for the treatment of psoriasis. Eur. J. Pharm. Biopharm., 2016, 107, 97-109.
[http://dx.doi.org/10.1016/j.ejpb.2016.06.019] [PMID: 27368748]
[95]
Panonnummal, R.; Sabitha, M. Anti-psoriatic and toxicity evaluation of methotrexate loaded chitin nanogel in imiquimod induced mice model. Int. J. Biol. Macromol., 2018, 110, 245-258.
[http://dx.doi.org/10.1016/j.ijbiomac.2017.10.112] [PMID: 29054520]
[96]
Naeff, R.; Delmenico, S.; Spycher, R.; Corbo, M.; Flother, F. Liposome-based Topical Vitamin D Formulation. U.S. Patent 5834016A, 2002.
[97]
Hunter, W.L. Composition and Methods of Paclitaxel for Treating Psoriasis. U.S. Patent 6515016B2, 2003.
[98]
Hans, W.; Schmid, G.B. Nano-emulsion of 5-aminolevulinic Acid. U.S. Patent 6559183B1, 2003.
[99]
Gidwani, S.K. Composition for Delivery of Dithranol. European Patent EP1364642, 2006.
[100]
Mills, R. Mahonia Aquifolium Extract, Extraction Process and Pharmaceutical Composition Containing the Same. U.S. Patent 7621740B2, 2007.
[101]
Simone, C.D. Use of Gamma Globulin for the Topical Treatment of Lesions of Dermatitis. U.S. Patent 7217416B2, 2007.
[102]
Naeff, R.; Delmenico, S. SpycherMike, R.; Flother, C. Liposomebased Topical Vitamin D Formulation. WIPO WO1997037637A1, 2008.
[103]
Sinan Tas, O.A. Use of Cyclopamine in the Treatment of Psoriasis 2009.
[104]
Perez, G.X. Liposomal Formulation of Clobetasol Propionate. European Patent Office, EP1360958A2, 2009.
[105]
Goebel, A.S.B. Microemulsion Pharmaceutical Composition Comprising a Macrolide Immunosuppressant Drug. U.S. Patent 8574562B2, 2013.
[106]
Mandip Singh Sachdeva, R.P. Nanoparticle Formulations for Skin Delivery. U.S. Patent 8715736B2, 2014.
[107]
Roy, S.B.; Kothari, J.S.; Sheikh, S.; Patel, J.D.; Pancholi, J.S. Topical Pharmaceutical Compositions Containing Nanodroplets for the Treatment Psoriasis. U.S. Patent 8992994B2, 2015.
[108]
Raghavan, P.R. Metadichol® Liquid and Gel Nanoparticle Formulations. U.S. Patent 9006292B2, 2015.
[109]
Foguet, R.M. Nanoemulsion. W.O. Patent 2008077641A1, 2016.
[110]
Kroon, H-A. Vesicular Formulations, U.S. Patent 9452179B2, 2016.
[111]
Shraibom, N. Herbal Nanoformulations for treating Psoriasis and other skin conditions. U.S. Patent 20190321430A1, 2017.
[112]
Kuí, Wǔ Shì; Huì, Wáng Dé; Long, Hé Chūn; Wén, Zhāng Huì; Yún, Wáng Huàn; Bīn, Wú; Wiāng, Cuī Hóng; Jié, Wáng Mǐn; Píng, Chén Jiàn; Dōng, Zhào Xiàng; Mǐn, Zāng Huì; Mǐn, Wáng; Càn, Wáng; Ruì, Lǐ Sī; Xiá, Kāng Shū; Yáo, Yáo; Qí, Qiáo; Jiāo, Xíng Tiān Preparation method and application of targeted mercury sulfide nanoparticle medicine. C.N. Patent 113304171A, 2021.
[113]
Píng, Y. Catechol and collagen tripeptide self-assembled nanocomposite, preparation and application thereof, 2021.
[114]
Jadhav, K.R.; Pawar, A.Y.; Bachhav, A.A.; Ahire, S.A. Proniosome: A novel non-ionic provesicules as potential drug carrier. Asian J. Pharm., 2016, 10(3), S210-S222.
[http://dx.doi.org/10.22377/ajp.v10i03.757]
[115]
Chandra, A.; Joshi, K.; Aggawwal, G. Topical nano drug delivery for treatment of psoriasis: progressive and novel delivery. Asian J. Pharmaceut., 2018, 12(3), S835-S848.
[116]
Steele, T.; Rogers, C.J.; Jacob, S.E. Herbal remedies for psoriasis: what are our patients taking? Dermatol. Nurs., 2007, 19(5), 448-450, 457-463.
[PMID: 18286859]

Rights & Permissions Print Cite
Article Metrics
9
1
© 2024 Bentham Science Publishers | Privacy Policy